0.04Open0.04Pre Close0 Volume214 Open Interest0.50Strike Price0.00Turnover7114.94%IV55.34%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type-0.0854Delta0.2125Gamma25.75Leverage Ratio-1.5656Theta0.0000Rho-2.20Eff Leverage0.0000Vega
Gossamer Bio Stock Discussion
loading...
loading...
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
No comment yet